Literature DB >> 28355508

Myasthenia Gravis.

Nils E Gilhus1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28355508     DOI： 10.1056/NEJMc1701027

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618

Review 2.  Complement Inhibitor Therapy for Myasthenia Gravis.

Authors:  Khaled Albazli; Henry J Kaminski; James F Howard
Journal:  Front Immunol       Date:  2020-06-03       Impact factor: 7.561

3.  Late-onset Myasthenia Gravis Accompanied by Amyotrophic Lateral Sclerosis with Antibodies against the Acetylcholine Receptor and Low-density Lipoprotein Receptor-related Protein 4.

Authors:  Keiko Ohnari; Kazumasa Okada; Osamu Higuchi; Hidenori Matsuo; Hiroaki Adachi
Journal:  Intern Med       Date:  2018-10-15       Impact factor: 1.271

4.  Cross-sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment.

Authors:  Gary Cutter; Haichang Xin; Inmaculada Aban; Ted M Burns; Phillip H Allman; Ramin Farzaneh-Far; Petra W Duda; Henry J Kaminski
Journal:  Muscle Nerve       Date:  2019-10-09       Impact factor: 3.217

5.  CXCR5-negative natural killer cells ameliorate experimental autoimmune myasthenia gravis by suppressing follicular helper T cells.

Authors:  Chun-Lin Yang; Peng Zhang; Ru-Tao Liu; Na Zhang; Min Zhang; Heng Li; Tong Du; Xiao-Li Li; Ying-Chun Dou; Rui-Sheng Duan
Journal:  J Neuroinflammation       Date:  2019-12-29       Impact factor: 8.322

Review 6.  Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis.

Authors:  Christian W Keller; Marc Pawlitzki; Heinz Wiendl; Jan D Lünemann
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.